Isofol Medical Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
ISOFOL
- Investments
-
1
- Share Price
-
$0.13
- (As of Thursday Closing)
Isofol Medical General Information
Description
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
Contact Information
Website
www.isofolmedical.comCorporate Office
- Biotech Center
- Arvid Wallgrens Backe 20
- 413 46 Gothenburg
- Sweden
Corporate Office
- Biotech Center
- Arvid Wallgrens Backe 20
- 413 46 Gothenburg
- Sweden
Isofol Medical Stock Performance
As of 22-May-2025, Isofol Medical’s stock price is $0.13. Its current market cap is $20.2M with 162M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.13 | $0.12 | $0.06 - $0.46 | $20.2M | 162M | 375K | -$0.03 |
Isofol Medical Financials Summary
As of 31-Dec-2024, Isofol Medical has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 22,187 | 22,187 | (1,395) | (3,108) |
| Revenue | 0 | 0 | 68 | 1,261 |
| EBITDA | (4,464) | (4,464) | (3,914) | (15,759) |
| Net Income | (4,112) | (4,112) | (3,488) | (15,751) |
| Total Assets | 8,920 | 8,920 | 14,068 | 20,120 |
| Total Debt | 0 | 0 | 0 | 0 |
Isofol Medical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Isofol Medical Comparisons
Industry
Financing
Details
Isofol Medical Competitors (1)
One of Isofol Medical’s competitors is Modus Therapeutics, a Formerly VC-backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Modus Therapeutics | Formerly VC-backed | Stockholm, Sweden |
Isofol Medical Patents
Isofol Medical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4534088-A1 | Arfolitixorin for use in vitamin b6-enhanced, 5-fluorouracil-based chemotherapy of carcinomas | Pending | 04-Oct-2023 | ||
| US-20240350467-A1 | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer | Pending | 20-Apr-2023 | ||
| US-20240350495-A1 | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of carcinoma | Pending | 20-Apr-2023 | ||
| EP-4450071-A1 | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer | Pending | 20-Apr-2023 | ||
| US-20230097085-A1 | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer | Inactive | 28-Sep-2021 | A61K31/519 |
Isofol Medical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Isofol Medical Investments (1)
Isofol Medical’s most recent deal was a Joint Venture with Dermafol. The deal was made on 01-Jan-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dermafol | 01-Jan-2010 | Joint Venture | Drug Discovery |
Isofol Medical ESG
Risk Overview
Risk Rating
Updated April, 24, 2024
34.08 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Isofol Medical FAQs
-
When was Isofol Medical founded?
Isofol Medical was founded in 2008.
-
Where is Isofol Medical headquartered?
Isofol Medical is headquartered in Gothenburg, Sweden.
-
What is the size of Isofol Medical?
Isofol Medical has 5 total employees.
-
What industry is Isofol Medical in?
Isofol Medical’s primary industry is Biotechnology.
-
Is Isofol Medical a private or public company?
Isofol Medical is a Public company.
-
What is Isofol Medical’s stock symbol?
The ticker symbol for Isofol Medical is ISOFOL.
-
What is the current stock price of Isofol Medical?
As of 22-May-2025 the stock price of Isofol Medical is $0.13.
-
What is the current market cap of Isofol Medical?
The current market capitalization of Isofol Medical is $20.2M.
-
Who are Isofol Medical’s competitors?
Modus Therapeutics is a competitor of Isofol Medical.
-
What is Isofol Medical’s annual earnings per share (EPS)?
Isofol Medical’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
